Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01AI095041 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| University of Witwatersrand, South Africa | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to use a cluster randomized trial to compare the effectiveness of linking the Quantiferon-gold in-tube test (QGIT) with routine CD4 testing to the routine use of the tuberculin skin test (TST), the current standard of care for diagnosing latent tuberculosis infection (LTBI) in South Africa. The investigators hypothesize that QGIT clinics will identify LTBI and initiate isoniazid preventive therapy (IPT) in a higher proportion of patients and in a significantly faster timeframe. The cost-effectiveness of linking QGIT with routine CD4 compared to routine TST will also be evaluated, and the process of implementation of QGIT into the routine cluster of differentiation 4 (CD4) blood draw will be evaluated using a mixed method approach to identify steps that can be modified for future scale-up of the intervention.
The investigators propose a cluster randomized trial in 16 HIV clinics in South Africa to compare time to determine LTBI status in patients in clinics using QGIT and TST and those with TST only. The investigators will take advantage of the excellent HIV services provided in South Africa and link QGIT with CD4 blood collection and provide the first evidence of an operational comparison between QGIT and TST in HIV-infected patients in a country that accounts for one-third of the HIV-related TB in the world. The QGIT study will contribute to the understanding of QGIT performance and implementation in HIV-infected individuals. Careful evaluation of the implementation and operational aspects of the program will provide useful knowledge for future scale-up in this and other HIV clinic settings.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TST only | No Intervention | Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out. | |
| QGIT | Experimental | QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| QGIT | Device | Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm. |
| Measure | Description | Time Frame |
|---|---|---|
| Impact of linking QGIT with CD4 blood collection and the current standard of care process of TST in HIV clinics in South Africa on operational metrics | Participants will be followed for the duration of the study, an expected average of 2 years | |
| Time to known latent TB infection status in clinics integrating QGIT with CD4 blood draw versus clinics with current standard of care (TST only) | Participants will be followed for the duration of the study, an expected average of 2 years | |
| Time to provision of IPT for eligible patients in QGIT versus TST-only clinics | Participants will be followed for the duration of the study, an expected average of 2 years | |
| Proportion of patients with known LTBI status in QGIT and TST-only clinics | Participants will be followed for the duration of the study, an expected average of 2 years | |
| Proportion of eligible patients receiving IPT between QGIT and TST-only clinics | Participants will be followed for the duration of the study, an expected average of 2 years | |
| Proportion of eligible patients receiving a second TST or QGIT following an initial negative test | Participants will be followed for the duration of the study, an expected average of 2 years | |
| Patient-, provider-, and clinic-level factors that impact outcomes within and between arms | Participants will be followed for the duration of the study, an expected average of 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Cost effectiveness of implementing QGIT versus TST-only | Costs and effectiveness (quality-adjusted life years) of LTBI screening and treatment with QGIT versus TST standard of care. Looking at the impact on the HIV-associated TB epidemic in South Africa under each strategy and scenarios under which QGIT is cost-effective relative to TST, and vice versa. | 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jonathan E Golub, PhD | Johns Hopkins University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bothabelo CHC | Klerksdorp | North West | South Africa | |||
| Grace Mokhomo |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39036871 | Derived | Jarrett BA, Shearer K, Motlhaoleng K, Chon S, Letuba GG, Qomfo C, Moulton LH, Cohn S, Lebina L, Chaisson RE, Variava E, Martinson NA, Golub JE. Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized Trial. Clin Infect Dis. 2024 Sep 26;79(3):751-760. doi: 10.1093/cid/ciae268. | |
| 29661197 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of key clinic personnel | Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening | up to 6 months |
| Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients | Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening | up to 6 months |
| Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of clinic personnel | Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening | 1 year |
| Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients | Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening | 1 year |
| Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of clinic personnel | Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening | 2 years |
| Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients | Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening | 2 years |
| Cost effectiveness of implementing QGIT versus TST-only | Costs and effectiveness (quality-adjusted life years) of LTBI screening and treatment with QGIT versus TST standard of care. Looking at the impact on the HIV-associated TB epidemic in South Africa under each strategy and scenarios under which QGIT is cost-effective relative to TST, and vice versa. | 2 years |
| Klerksdorp |
| North West |
| South Africa |
| Jouberton | Klerksdorp | North West | South Africa |
| Marcus Zenzile | Klerksdorp | North West | South Africa |
| NM Pretorious Gateway | Klerksdorp | North West | South Africa |
| Orkney | Klerksdorp | North West | South Africa |
| Park Street | Klerksdorp | North West | South Africa |
| Stilfontein | Klerksdorp | North West | South Africa |
| Tshepong Wellness Clinic | Klerksdorp | North West | South Africa |
| Tsholofelo | Klerksdorp | North West | South Africa |
| Boiki Tihapi | Potchefstroom | North West | South Africa |
| Potchefstroom Gateway | Potchefstroom | North West | South Africa |
| Potchefstroom | Potchefstroom | North West | South Africa |
| Steve Tshwete | Potchefstroom | North West | South Africa |
| Kerrigan D, Tudor C, Motlhaoleng K, Lebina L, Qomfu C, Variava E, Chon S, Martinson N, Golub JE. Relevance and acceptability of using the Quantiferon gold test (QGIT) to screen CD4 blood draws for latent TB infection among PLHIV in South Africa: formative qualitative research findings from the TEKO trial. BMC Health Serv Res. 2018 Apr 16;18(1):288. doi: 10.1186/s12913-018-3088-8. |
| ID | Term |
|---|---|
| D055985 | Latent Tuberculosis |
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D000085343 | Latent Infection |
Not provided
Not provided